Recurrence Status, Perineural Invasion, and Hypothyroidism Are Associated With Lymph Node Metastasis in Cutaneous Squamous Cell Carcinoma: A Case-Control Study.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
8
2
2022
medline:
9
4
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
Lymph node metastasis is a critical prognostic indicator for mortality in patients with cutaneous squamous cell carcinoma (SCC). To identify and characterize key risk factors for SCC lymph node metastasis. This was a multi-institutional, case-control study of 65 cutaneous SCCs with known lymph node metastasis matched with 195 cutaneous SCCs without lymph node metastasis (3:1 matching). The cases and controls were matched by anatomic location, age, and sex. Odds ratios (ORs) and their 95% confidence intervals (CIs) were generated to determine the association between specific risk factors and lymph node metastasis in a multivariate analysis. Recurrent tumors (p < .001), perineural invasion (p < .001), lymphovascular invasion (p = .002), size of 2 cm or greater (p = .008), and hypothyroidism (p = .03) were significantly more common in the lymph node metastasis cohort. Recurrence (OR 6.3, 95% CI 2.6-15.3), perineural invasion (OR 4.5, 95% CI 1.7-11.8), and hypothyroidism (OR 2.7, 95% CI 1.04-7.0) remained significant on performing a multivariate analysis. Lymph node metastasis in SCC is associated with recurrence, perineural invasion, lymphovascular invasion, size of 2 cm or greater, and hypothyroidism. Clinical consideration of these findings within the context of current staging systems may help improve patient outcomes.
Sections du résumé
BACKGROUND
Lymph node metastasis is a critical prognostic indicator for mortality in patients with cutaneous squamous cell carcinoma (SCC).
OBJECTIVE
To identify and characterize key risk factors for SCC lymph node metastasis.
METHODS
This was a multi-institutional, case-control study of 65 cutaneous SCCs with known lymph node metastasis matched with 195 cutaneous SCCs without lymph node metastasis (3:1 matching). The cases and controls were matched by anatomic location, age, and sex. Odds ratios (ORs) and their 95% confidence intervals (CIs) were generated to determine the association between specific risk factors and lymph node metastasis in a multivariate analysis.
RESULTS
Recurrent tumors (p < .001), perineural invasion (p < .001), lymphovascular invasion (p = .002), size of 2 cm or greater (p = .008), and hypothyroidism (p = .03) were significantly more common in the lymph node metastasis cohort. Recurrence (OR 6.3, 95% CI 2.6-15.3), perineural invasion (OR 4.5, 95% CI 1.7-11.8), and hypothyroidism (OR 2.7, 95% CI 1.04-7.0) remained significant on performing a multivariate analysis.
CONCLUSION
Lymph node metastasis in SCC is associated with recurrence, perineural invasion, lymphovascular invasion, size of 2 cm or greater, and hypothyroidism. Clinical consideration of these findings within the context of current staging systems may help improve patient outcomes.
Identifiants
pubmed: 35125444
doi: 10.1097/DSS.0000000000003396
pii: 00042728-202204000-00001
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-386Informations de copyright
Copyright © 2022 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015;151:1081–6.
Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, lymph node metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68:957–66.
Clayman GL, Lee JJ, Holsinger FC, Zhou X, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005;23:759–65.
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344:975–83.
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013;149:402–10.
Mullen JT, Feng L, Xing Y, Mansfield PF, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006;13:902–9.
Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 2014;150:19–24.
Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2013;32:327–34.
Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer staging manual, 8th edition vs the Brigham and Women's Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019;155:819–25.
Feinstein S, Higgins S, Wysong A. A retrospective cohort study of cutaneous squamous cell carcinoma with lymph node metastasis: risk factors and clinical course. Dermatol Surg 2019;45:772–81.
Ahadiat O, Higgins S, Trodello C, Talmor G, et al. Hypothyroidism potentially linked to cutaneous squamous cell carcinoma: retrospective study at a single tertiary Academic Medical Center. Dermatol Surg 2018;44:10–6.
Mandrekar JN, Mandrekar SJ. Case-control study design: what, when, and why? J Thorac Oncol 2008;3:1371–2.
Ury HK. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975;31:643–9.
Leibovitch I, Huilgol SC, Selva D, Hill D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005;53:261–6.
Garcia‐Serra A, Hinerman RW, Mendenhall WM, Amdur RJ, et al. Carcinoma of the skin with perineural invasion. Head & neck 2003;25:1027–33.
Carter JB, Johnson MM, Chua TL, Karia PS, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol 2013;149:35–41.
Moore BA, Weber RS, Prieto V, El-Naggar A, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:1561–7.
Veness MJ. High-risk cutaneous squamous cell carcinoma of the head and neck. J Biomed Biotechnol 2007;2007:80572.
Rose AE, Christos PJ, Lackaye D, Shapiro RL, et al. Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34. Am J Surg Pathol 2011;35:1441–9.
Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976–90.
Grover R, Douglas RG, Shaw JH. Carcinoma of the lip in Auckland, New Zealand, 1969-1987. Head Neck 1989;11:264–8.
Pugliano Mauro M, Goldman G. Mohs surgery is effective for high‐risk cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:1544–53.
Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol 2019;80:633–8.
Slominski A, Wortsman J, Kohn L, Ain KB, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol 2002;119:1449–55.
Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, et al. Human melanoma cells express functional receptors for thyroid-stimulating hormone. Endocr Relat Cancer 2006;13:1269–77.
Genders RE, Weijns ME, Dekkers OM, Plasmeijer EI. Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019;33:828–41.
Wysong A, Higgins S, Blalock TW, Ricci D, et al. Defining skin cancer local recurrence. J Am Acad Dermatol 2019;81:581–99.